UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009358
Receipt number R000010995
Scientific Title Development of oral taurine therapy for the treatment of MERRF
Date of disclosure of the study information 2012/11/19
Last modified on 2018/10/09 15:52:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Development of oral taurine therapy for the treatment of MERRF

Acronym

Taurine therapy for MERRF

Scientific Title

Development of oral taurine therapy for the treatment of MERRF

Scientific Title:Acronym

Taurine therapy for MERRF

Region

Japan


Condition

Condition

MERRF

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To evaluate the efficacy of taurine to prevent disease progression of MERRF

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

-Frequency of seizure
-Clinical score of cerebellar ataxia

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Ten patients with MERRF having A8344G mutations in the mitochondrial DNA are enrolled in the study. Oral taurine (12g/d) is administered to the patients for 24 months to evaluate its effect on preventing epileptic symptoms and the progression of cerebellar ataxia.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Male and female patients over 16 years old

Key exclusion criteria

none

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yutaka Ohsawa

Organization

Kawasaki Medical School

Division name

Neurology

Zip code


Address

577 Matsusima, Kurashiki-city, Okayama 701-0192, Japan

TEL

086-462-1111

Email

yosawa@med.kawasaki-m.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yutaka Ohsawa

Organization

Kawasaki Medical School

Division name

Neurology

Zip code


Address

577 Matsusima, Kurashiki-city, Okayama 701-0192, Japan

TEL

086-462-1111

Homepage URL


Email

yosawa@med.kawasaki-m.ac.jp


Sponsor or person

Institute

Department of Neurology, Kawasaki Medical School

Institute

Department

Personal name



Funding Source

Organization

Department of Neurology, Kawasaki Medical School

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Department of Biochemistry and Cell Biology, Institute of Development and Aging Sciences, Nippon Medical School

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

川崎医科大学附属病院(岡山県)


Other administrative information

Date of disclosure of the study information

2012 Year 11 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 11 Month 19 Day

Date of IRB


Anticipated trial start date

2012 Year 12 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 11 Month 19 Day

Last modified on

2018 Year 10 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010995


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name